Показано 0 из 0
Дата |
---|
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
19.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.41
|
5.08
|
4.31
|
4.31
|
4.31
|
4.31
|
|
|
|
|
4.33
|
5.08
|
5.42
|
4.28
|
5.42
|
4.99
|
|
|
2 674.00
|
3.00
|
5.66
|
6.30
|
5.96
|
5.96
|
5.96
|
5.96
|
|
|
|
|
5.96
|
6.86
|
5.96
|
5.96
|
5.96
|
5.96
|
|
|
|
|
6.20
|
6.88
|
6.08
|
6.08
|
6.08
|
6.08
|
|
|
|
|
6.06
|
6.40
|
6.00
|
6.00
|
6.00
|
6.00
|
|
|
|
|
6.00
|
6.80
|
6.40
|
6.40
|
6.40
|
6.40
|
|
|
|
|
6.52
|
7.00
|
6.56
|
6.56
|
6.56
|
6.56
|
|
|
|
|
6.56
|
7.00
|
6.74
|
6.74
|
6.74
|
6.74
|
|
|
|
|
6.80
|
7.30
|
7.00
|
7.00
|
7.00
|
7.00
|
|
|
|
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.